New Launch7 Apr 2025, 02:09 pm
Sun Pharma Launches Novel Drug Fexuclue® for Erosive Esophagitis Treatment in India
AI Summary
Sun Pharmaceutical Industries Ltd. has launched Fexuprazan tablets 40 mg in India under the brand name ‘FEXUCLUE®’. FEXUCLUE® is a novel potassium-competitive acid blocker (PCAB) approved for the treatment of adults with Erosive Esophagitis of all grades. The drug has a fast onset of action, stable suppression of gastric acid, and can be taken regardless of food intake. It has the longest half-life of 9 hours among P-CABs, implying longer duration of acid suppression which helps to achieve optimal nocturnal symptom control. The drug was evaluated in a double-blind, double-dummy, comparative Phase 3 study in adult Indian population and found to be well tolerated.
Key Highlights
- Sun Pharma launches Fexuprazan tablets 40 mg in India under the brand name ‘FEXUCLUE®’
- FEXUCLUE® is a novel potassium-competitive acid blocker (PCAB) approved for the treatment of adults with Erosive Esophagitis of all grades
- FEXUCLUE® has a fast onset of action, stable suppression of gastric acid, and can be taken regardless of food intake
- Fexuprazan has the longest half-life of 9 hours among P-CABs, implying longer duration of acid suppression
- The drug was found to be well tolerated in Indian patients